Abstract
The affinities of a range of structurally diverse 5-HT3 receptor agonists and antagonists for [3H]-granisetron binding sites have been measured in membrane homogenates prepared from central and peripheral tissues of the mouse. By comparing the affinities of compounds across these tissues, the question of whether intea-species 5-HT3 receptor subtypes exist in the mouse has been addressed.
In entorhinal cortex and brainstem, [3H]-granisetron bound to a single high affinity saturable binding site (Kd 0.47 ± 0.14 and 0.60 ± 0.05 nM; B max 20 ± 6 and 7 ± 2 fmol (mg protein)−1 respectively; mean ±SEM; n = 3). In distal and proximal colon, the specific binding of [3H]-granisetron was best fitted to a 2-site model. Kd values obtained for the high affinity site were similar to those obtained in brain tissue (distal colon: 0.47 ± 0.09 nM, n = 4; proximal colon: 0.39 ± 0.09 nM, n = 4). In salivary gland, 2-sites were evident in 2 out of 4 experiments. The Kd value (calculated from the high affinity site in the 2-site model) was approximately 10-fold less than in brain or colon (3.3 ± 1.1 nM, n = 4). B max values were 7 ± 2, 4 ± 1 and 71 ± 16 fmol (mg protein)−1 for distal colon, proximal colon and salivary gland respectively. For all tissues the estimated affinity of the low affinity site was variable, and B max values could not be reliably calculated.
Extensive comparative studies performed with 17 different 5-HT3 receptor agonists and antagonists in the five tissues did not reveal differences in affinity for any compound between the entorhinal cortex and the brainstem nor between the two regions of the colon. However, MDL72222, R-zacopride, d-tubocurarine, and GR80284 apparently had significantly lower affinity for colon than brain binding sites. Also, MDL72222, 2-methyl-5-HT, GR80284, 1-(m-chlorophenyl)-biguanide, metoclopramide, and granisetron had significantly lower affinity for the salivary gland binding sites than the brain binding sites. In an attempt to replicate these observations, we conducted a second study using the compounds which had shown the largest inter-tissue differences in affinity keeping as many variables as possible constant. Simultaneous comparative assays on entorhinal cortex, colon and salivary gland homogenates taken from the same mice showed that the differences that were apparent in the initial comparative study were not maintained. In conclusion, we can find no clear evidence for the existence of tissue-specific subtypes of the 5-HT3 high affinity binding site for [3H]-granisetron in the mouse in the tissues tested. However, a low affinity binding site for [3H]-granisetron was detected in peripheral tissues.
Similar content being viewed by others
References
Bachy A, Heaulme M, Giudice A, Michaud JC, Lefevre IA, Souilhac J, Manara L, Emerit MB, Gozlan H, Hamon M, Keane PE, Soubric P, Lefur G (1993) SR-57227A-a potent and selective agonist at 5-HT3 receptors in vitro and in vivo. Eur J Pharmacol 237:299–309
Bockaert J, Sebben M, Dumuis A (1990) Pharmacological characterisation of 5-hydroxytryptamine4 (5-HT4) receptors positively coupled to adenylate cyclase in adult guinea-pig hippocampal membranes: Effect of substituted benzamide derivatives. Mol Pharmacol 37:408–411
Bonhaus DW, Wong EHF, Stefanich E, Kunysz EA, Eglen R (1993) Pharmacological characterization of 5-hydroxytryptamine3 receptors in murine brain and ileum using the novel radioligand [3H]-RS-42358–197: evidence for receptor heterogeneity. J Neurochem 61:1927–1932
Bradford M (1976) A rapid and sensitive method for quantitation of microgram quantities of proteins utilising the principles of protein-dye binding. Anal Biochem 72:248–254
Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylcharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576
Butler A, Elswood CJ, Burridge J, Ireland SJ, Bunce KT, Kilpatrick GJ, Trees MB (1990) The pharmacological characterisation of 5-HT3 receptors in three isolated preparations derived from guinea-pig tissues. Br J Pharmacol 101:591–598
De Lean A, Munson PJ, Rodbard D (1977) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol 235:E97
Denens ES, Connolly J, Rogers SW, Duvoisin R (1991) Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol Sci 12:34–40
Fozard JR (1983) Differences between receptors for 5-hydroxytryptamine on autonomic nerves revealed by nor-(−)-cocaine. J Auton Pharmacol 3:21–26
Gebauer A, Merger M, Kilbinger H (1993) Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn-Schmiedeberg's Arch Pharmacol 347:137–140
Kilpatrick GJ, Tryes MB (1992) Inter-species variants of the 5-HT3 receptor. Biochem Soc Trans 20:118–121
Kilpatrick GJ, Jones BJ, Tryes MB (1989) Binding of the 5-HT3 ligand, [3H]-GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159:157–164
Kursar JD, Nelsen DL, Wainscott DB, Cohen ML, Baez M (1992) Molecular cloning, functional expression and pharmacological characterisation of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol 42:547–549
Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat J-L, Muscatelli F, Mattei M-G, Hen R (1993) Mouse 5-hydroxytryptramine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: Cloning, functional expression and chromosomal localisation. Mol Pharmacol 43:320–327
Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D (1991) Primary structure and functional expression of the 5-HT3 receptor, a serotonin-gated ion channel. Science 254:432–437
Monsma FJJr, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43:320–327
Munson PJ, Rodbard D (1980) LIGAND: a versatile computerised approach for characterisation of ligand binding systems. Anal Biochem 107:220–230
Nelson DR, Thomas DR (1989) [3H]-BRL43694 (Granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem Pharmacol 38:1693–1695
Newberry NR, Cheshire SH, Gilbert MJ (1991) Evidence that the 5-HT3 receptors of the rat, mouse and guinea-pig superior cervical ganglion may be different. Br J Pharmacol 102:615–620
Richardson BP, Engel G, Donatsch P, Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316:126–131
Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR (1993) Molecular cloning and expression of a 5-HT7 serotonin receptor subtype. J. Biol Chem 268:18200–18204
Waeber C, Dixon K, Hoyer D, Palacios JM (1988) Localization by autoradiography of neuronal 5-HT3 receptors in the mouse. Eur J Pharmacol 151:351–352
Wong EHF, Bonhaus DW, Stefanich E, Eglen RM (1993) Labelling of 5-hydroxytryptamine3 receptors with a novel 5-HT3 receptor ligand, [3H]-RS-42358–197. J Neurochem 60:921–930
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perren, M.J., Rogers, H., Mason, G.S. et al. A pharmacological comparison of [3H]-granisetron binding sites in brain and peripheral tissues of the mouse. Naunyn-Schmiedeberg's Arch Pharmacol 351, 221–228 (1995). https://doi.org/10.1007/BF00233240
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00233240